Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Tuberous Sclerosis 3

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × ganaxolone × Clear all
NCT05604170 2025-10-01

Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy

Marinus Pharmaceuticals

Phase 3 Terminated
117 enrolled 11 charts

Tuberous Sclerosis

NCT05323734 2025-07-11

Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

Marinus Pharmaceuticals

Phase 3 Completed
129 enrolled 13 charts

Tuberous Sclerosis

NCT04285346 2023-04-04

TSC

Marinus Pharmaceuticals

Phase 2 Completed
23 enrolled 9 charts

Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡